Kaplan-Meier curves for overall survival (A) and progression-free... | Download Scientific Diagram
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis - Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner,
Diagnostics | Free Full-Text | Prognostic Factors Associated with 5-Year Overall Survival in Cervical Cancer Patients Treated with Radical Hysterectomy Followed by Adjuvant Concurrent Chemoradiation Therapy at a Tertiary Care Center in
The role of censoring on progression free survival: Oncologist discretion advised - ScienceDirect
Breast Cancer Survival Rates: Prognosis by Age, Race & More
SOLO-2: Overall Survival Data on Olaparib for Relapsed, BRCA-Mutated Ovarian Cancer
Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study - The Lancet Oncology
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis | PLOS ONE
Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis | Radiation Oncology | Full Text
Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis | Scientific Reports
Pancancer survival analysis of cancer hallmark genes | Scientific Reports
Overall survival for chemotherapy-treated and-untreated patients with... | Download Scientific Diagram
Understanding Survival Analysis in Clinical Trials - Clinical Oncology
Overall survival and breast-cancer-specific survival curves according... | Download Scientific Diagram
Prognostic factors in epithelial ovarian cancer: A population-based study | PLOS ONE
Figure 1 from Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. | Semantic Scholar
Overall survival (OS) curves in each gastric cancer (GC) pathological... | Download Scientific Diagram
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status | Journal for ImmunoTherapy of Cancer
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer | BMC Cancer | Full Text
Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing r
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Frontiers | Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Kaplan-Meier curve of progression-free survival (PFS) (a) and overall... | Download Scientific Diagram
Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
